RG 125
Alternative Names: AZD 4076; RG125Latest Information Update: 31 Oct 2021
At a glance
- Originator AstraZeneca; Regulus Therapeutics
- Class Antisense oligonucleotides; MicroRNAs
- Mechanism of Action MIRN103 microRNA inhibitors; MIRN103 microRNA modulators; MIRN107 microRNA inhibitors; MIRN107 microRNA modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
Most Recent Events
- 02 Aug 2017 Discontinued - Phase-II for Non-alcoholic fatty liver disease in USA (SC) (AstraZeneca pipeline, August 2017)
- 02 Aug 2017 Discontinued - Phase-II for Non-alcoholic steatohepatitis in USA (SC) (AstraZeneca pipeline, August 2017)
- 07 Jul 2017 Phase-II clinical trials in Non-alcoholic fatty liver disease in USA (SC) (AstraZeneca pipeline, July 2017)